Phaseline

Targets › GRIK1

GRIK1 (Glutamate receptor ionotropic, kainate 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Psychiatry; next expected readout Oct 2027.

Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. (UniProt, P39086)

Open in Phaseline: the race on GRIK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PronirasTezampanel
Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist
GRIA4, GRIA3, GRIA2, GRIA1, GRIK1Phase 1Opioid Use DisorderOct 2027

Conditions

Opioid Use Disorder (1)

Modalities

small molecule (1)

Companies

Proniras (1)

Related targets

GRIA4 (1) GRIA3 (1) GRIA2 (1) GRIA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.